

Clinical features of COVID-19 patients in Abdul Wahab Sjahranie Hospital, Samarinda, Indonesia

Swandari Paramita^{*1,2}, Ronny Isnuwardana², Marwan Marwan^{2,3}, Donny Irfandi Alfian³,
David Hariadi Masjhoer³

¹Center of Excellence for Tropical Studies, Mulawarman University, Samarinda, Indonesia

²Faculty of Medicine, Mulawarman University, Samarinda, Indonesia

³Abdul Wahab Sjahranie Hospital, Samarinda, Indonesia

*Corresponding Author: s.paramita@fk.unmul.ac.id

Abstract

Introduction

Coronavirus Disease (COVID-19) is caused by SARS-CoV-2 infection. Indonesia officially established the first COVID-19 confirmation case in early March 2020. East Kalimantan has been determined as a candidate for the new capital of Indonesia since 2019. This makes Abdul Wahab Sjahranie Hospital Samarinda as the largest hospital there has been designated as the main referral hospital for COVID-19 patients in East Kalimantan. We report the epidemiological, clinical, laboratory, and radiological characteristics of these patients.

Methods

All patients with laboratory-confirmed COVID-19 by RT-PCR were admitted to Abdul Wahab Sjahranie Hospital in Samarinda. We retrospectively collected and analyzed data on patients with standardized data collection from medical records.

Results

By May 8, 2020, 18 admitted hospital patients had been identified as having laboratory-confirmed COVID-19. Most of the infected patients were men (16 [88.9%] patients); less than half had underlying diseases (7 [38.9%] patients). Common symptoms at the onset of illness were cough (16 [88.9%] patients), sore throat (8 [44.4%] patients), and fever (8 [44.4%] patients). Laboratory findings of some patients on admission showed anemia. Levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were increased in 10

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

32 (55.6%) of 18 patients. On admission, abnormalities in chest x-ray images were detected in 6
33 (33.3%) patients who had pneumonia. The mean duration from the first hospital admission
34 to discharge was 33.1 ± 9.2 days.

35 **Discussion**

36 The majority of COVID-19 patients are male. COVID-19 comorbidities were found in several
37 patients. The main clinical symptoms of COVID-19 in this study were cough, sore throat, and
38 fever. The abnormal laboratory finding in COVID-19 patients is anemia, an increase in AST and
39 ALT levels, and chest x-ray images of pneumonia. All patients are in mild condition. The
40 average length of hospital admission patients to discharge is more than 30 days.

41 **Conclusion**

42 Although all patients are in mild condition, the inability of a local laboratory to check for
43 positive confirmation of COVID-19 makes the admission period of the patient in the hospital
44 very long. The availability of RT-PCR tests at Abdul Wahab Sjahranie Hospital Samarinda will
45 greatly assist the further management of COVID-19 patients.

46

47 **Introduction**

48 Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome
49 coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2, an RNA virus from the Coronaviridae
50 family, can be transmitted to humans and animals (1). Although most coronavirus infections
51 in humans are mild, there have been two epidemics of beta coronavirus throughout history,
52 namely severe acute respiratory syndrome (SARS) (2) and Middle East respiratory syndrome
53 (MERS) (3), which have caused more than 10,000 cases in the last two decades, with a
54 mortality rate of 10% for SARS (4) and 37% for MERS (5).

55 In December 2019, a series of pneumonia cases with unknown causes emerged in Wuhan,
56 China, in which the clinical findings are similar to viral pneumonia. (6). The sequencing
57 analysis from respiratory tract samples indicated a new coronavirus, which was then named
58 SARS-CoV-2 (7). Until the end of May 2020, there are more than 5 million positive confirmed
59 cases of COVID-19 worldwide, with the USA, Brazil, and Russia as countries for the most cases
60 in the world (8).

61 Indonesia officially established its first COVID-19 confirmation case on March 2, 2020 from
62 the capital of Jakarta (9). Meanwhile the first case of COVID-19 from East Kalimantan, a

63 province of Indonesia in Borneo island, was reported on March 18, 2020, which was a patient
64 from Abdul Wahab Sjahranie Hospital in Samarinda city (10).

65 East Kalimantan province has been determined as a candidate for the new capital of the
66 Republic of Indonesia by 2019 (11). Therefore, the flow of people in and out of East
67 Kalimantan has been increasing rapidly, especially in Samarinda as the capital of the province.
68 This movement of people plays an important role in the spread of COVID-19 in Samarinda.
69 Abdul Wahab Sjahranie Hospital, the largest hospital in Samarinda, has been designated as
70 the main referral hospital for COVID-19 patients in Samarinda (12). Currently, there is no
71 previous study has been done which describe the COVID-19 cases from East Kalimantan.
72 Therefore, the study aims to describe the epidemiological, clinical, laboratory, and
73 radiological characteristics of COVID-19 patients who are admitted at Abdul Wahab Sjahranie
74 Hospital Samarinda.

75

76 **Methods**

77 ***Patients***

78 The subjects in this study were all patients admitted at Abdul Wahab Sjahranie Hospital with
79 laboratory confirmation of positive COVID-19 results from nasopharyngeal swabs from March
80 to May 2020. This study was approved by the Ethical Health Research Commission of Abdul
81 Wahab Sjahranie Hospital (No. 070/Diklit/1328/IV/2020).

82 ***Procedures***

83 Nasopharyngeal swab samples were taken when the patient was admitted to the hospital,
84 then the samples were sent to the Center for Health Laboratory in Surabaya, Indonesia as an
85 official examination laboratory for COVID-19 by the Ministry of Health of the Republic of
86 Indonesia.

87 Nasopharyngeal swabs samples were then examined to confirm COVID-19 using RT-PCR
88 according to guidelines from the Ministry of Health of the Republic of Indonesia. A positive
89 COVID-19 patient with clinical improvement can be discharged from the hospital if the follow-
90 up results of RT-PCR examination from nasopharyngeal swab samples of two days in a row
91 show negative results.

92 ***Data collection***

93 This study collected data on the hospital medical records of all patients with positive
94 confirmation of COVID-19. Data was taken from patients admitted to the hospital from March

95 14, 2020 to May 2, 2020. Epidemiological, clinical, laboratory and radiological data of patients
96 were reviewed with standardized data collection forms from hospital medical records. Two
97 researchers independently reviewed data collection to double-check the data obtained.

98 **Statistical analysis**

99 Continuous variables were expressed as mean \pm SD; categorical variables were expressed as
100 frequency and percentage. Statistical analyses were done using Microsoft Excel.

101

102 **Results**

103 By May 8, 2020, 18 admitted hospital patients had been identified as having laboratory-
104 confirmed COVID-19. Five (27.8%) of the COVID-19 patients were aged 30-39 years, and 4
105 (22.2%) were aged 60-69 years. The mean age of the patients was 44 ± 15.5 years. Most of
106 the infected patients were men (16 [88.9%]); less than half had underlying diseases (7
107 [38.9%]), including hypertension (4 [22.2%]), cardiovascular disease (2 [11.1%]), and diabetes
108 (1 [5.56%]).

109 The most common symptoms at onset of illness were cough (16 [88.9%] of 18 patients), sore
110 throat (8 [44.4%]), and fever (8 [44.4%]); less common symptoms were runny nose (7 [38.9%],
111 myalgia or fatigue (6 [33.3%]), dyspnea (5 [27.8%]), headache (4 [22.2%]), and nausea (4
112 [22.2%]). The mean duration from first hospital admission to COVID-19 laboratory
113 confirmation was 10 ± 3.6 days, and to hospital discharge was 33.1 ± 9.2 days.

114 The blood counts of patients on admission showed leukocytosis (white blood cell count more
115 than $10.8 \times 10^9/L$; 2 [11.1%] of 18 patients), lymphopenia (lymphocyte count $< 19\%$; 3 [16.7%]
116 patients), neutrophilia (neutrophil count $> 74\%$; 3 [16.7%] patients), and monocytosis
117 (monocytes count $> 9\%$; 3 [16.7%] patients). Laboratory findings of patients on admission also
118 showed low hemoglobin level (hemoglobin < 14 g/L; 6 [33.3%] patients), low erythrocytes
119 count (red blood cell count $< 4.7 \times 10^6$ per L; 5 [27.8%] patients), and high platelet large cell
120 ratio (P-LCR > 25 g/L; 4 [22.2%] patients). All patients had high platelet distribution width
121 (PDW > 13 g/L) on admission. Levels of aspartate aminotransferase (AST) and alanine
122 aminotransferase (ALT) were increased in 10 (55.6%) of 18 patients. All patients had normal
123 serum levels of procalcitonin on admission (0.26 ± 0.1 u/L). On admission, abnormalities in
124 radiographic images were detected in 6 (33.3%) patients which had pneumonia.

125 As of May 23, 2020, all patients have been discharged. Patients with clinical improvement can
126 be discharged from the hospital if the results of RT-PCR examination two days in a row show
127 negative results.

128

129 **Table 1. Demographics and baseline characteristics of COVID-19 patients**

130

Characteristics	Mean ± SD or N (%)
Age, years	44 ± 15.5
20-29 years	3 (16.7)
30-39 years	5 (27.8)
40-49 years	3 (16.7)
50-59 years	3 (16.7)
60-69 years	4 (22.2)
Sex	
Men	16 (88.9)
Women	2 (11.1)
Sources of transmission	
Imported cases from Gowa, South Sulawesi	12 (66.7)
Imported cases from other places	6 (33.3)
Local transmission within Samarinda	0 (0)
History of comorbidity	7 (38.9)
Hypertension	4 (22.2)
Cardiovascular disease	2 (11.1)
Diabetes mellitus	1 (5.6)
BMI, kg/m ²	23.7 ± 2.8
BMI > 25 kg/m ²	5 (27.8)

131

132

133 **Table 2. Signs and symptoms characteristics of COVID-19 patients**

134

Signs and symptoms	Mean ± SD or N (%)
--------------------	--------------------

Systolic pressure, mmHg	128.8 ± 17.7
Diastolic pressure, mmHg	83.5 ± 11.6
Blood pressure ≥ 140/90 mmHg	7 (38.9)
Respiratory rate, per min	20.7 ± 1.6
Temperature, °C	36.7 ± 0.6
Temperature ≥ 37 °C	8 (44.4)
Cough	16 (88.9)
Sore throat	8 (44.4)
Fever	8 (44.4)
Runny nose	7 (38.9)
Myalgia or fatigue	6 (33.3)
Dyspnea	5 (27.8)
Headache	4 (22.2)
Nausea	4 (22.2)
Days from the first admission to COVID-19 confirmation	10 ± 3.6
Days from the first admission to hospital discharge	33.1 ± 9.2

135

136

137 **Table 3. Laboratory findings of COVID-19 patients on hospital admission**

138

Laboratory findings	Mean ± SD or N (%)
Red blood cell count, x10 ⁶ per L	5.1 ± 0.6
Red blood cell count < 4.7 x10 ⁶ per L	5 (27.8)
Hemoglobin, g/L	14.7 ± 1.9
Hemoglobin < 14 g/L	6 (33.3)
Hematocrit, g/L	43.8 ± 4.7
Hematocrit < 37 g/L	2 (11.1)
Mean Corpuscular Volume (MCV), g/L	86.3 ± 5.4
MCV <81 g/L	2 (11.1)
Mean Corpuscular Hemoglobin (MCH), g/L	29.1 ± 2.4
MCH <27 g/L	2 (11.1)

MCH >31 g/L	2 (11.1)
Mean Corpuscular Hemoglobin Concentration (MCHC), g/L	33.6 ± 1.1
MCHC <33 g/L	1 (5.6)
Red Cell Distribution Width – Standard Deviation (RDW-SD), g/L	40.4 ± 2.6
Red Cell Distribution Width – Corpuscular Volume (RDW-CV), g/L	13.3 ± 1.4
RDW-CV > 14.5 g/L	1 (5.6)
Platelet count, x10 ³ per L	280.6 ± 85.9
Platelet count < 150 x10 ³ per L	1 (5.6)
Platelet Distribution Width (PDW), g/L	16.1 ± 0.3
PDW > 13 g/L	18 (100)
Mean Platelet Volume (MPV), g/L	9.3 ± 0.8
Platelet Large Cell Ratio (P-LCR), g/L	22.8 ± 6.1
P-LCR < 15 g/L	1 (5.6)
P-LCR > 25 g/L	4 (22.2)
Procalcitonin (PCT), g/L	0.26 ± 0.1
Aspartate aminotransferase (AST), U/L	43.4 ± 23.6
AST > 40 U/L	10 (55.6)
Alanine aminotransferase (ALT), U/L	56.6 ± 53.6
ALT > 41 U/L	10 (55.6)

139

140

141 **Table 4. White blood cell laboratory findings of COVID-19 patients on hospital admission**

142

Laboratory findings	Mean ± SD or N (%)
White blood cell count, x10 ³ per L	7.8 ± 2.3
White blood cell count > 10.8 x10 ³ per L	2 (11.1)
Neutrophil count, x10 ⁹ per L	4.8 ± 2.2
Neutrophil count > 7 x10 ⁹ per L	2 (11.1)
Neutrophil count, %	59.9 ± 13.4
Neutrophil count > 74%	3 (16.7)
Neutrophil count < 40%	1 (5.6)

Lymphocytes count, x10 ⁹ per L	2.3 ± 1.1
Lymphocytes count, %	30.6 ± 12.3
Lymphocytes count > 48%	1 (5.6)
Lymphocytes count < 19%	3 (16.7)
Monocytes count, x10 ⁹ per L	0.5 ± 0.1
Monocytes count, %	6.9 ± 1.9
Monocytes count > 9%	3 (16.7)
Eosinophils count, x10 ⁹ per L	0.2 ± 0.2
Eosinophil count > 0,8 x10 ⁹ per L	1 (5.6)
Eosinophils count, %	2.7 ± 2.4
Eosinophil count >7%	1 (5.6)

143

144

145 **Table 5. Radiographs findings of COVID-19 patients on hospital admission**

146

Radiographs findings	
Abnormalities in chest x-ray	
Ground glass opacity appearance	4 (22.2)
Unilateral	2 (11.1)
Bilateral	2 (11.1)
Consolidation appearance	2 (11.1)
Diagnoses on hospital admission based on chest x-ray	
Pneumonia	6 (27.8)

147

148

149 Discussion

150 This study reports of 18 patients with positive COVID-19 confirmations admitted at Abdul
 151 Wahab Sjahranie Hospital Samarinda, Indonesia. As of May 24, 2020, there have been 276
 152 positive COVID-19 positive confirmation cases in East Kalimantan (13). There are 22,271
 153 positive confirmed cases of COVID-19, with 5,402 people recovering and 1,372 patients have
 154 died in Indonesia on May 24, 2020 (14).

155 The majority of COVID-19 patients in Abdul Wahab Sjahranie Hospital are male. This is
156 consistent with a meta-analysis study which showed that men took the largest percentage in
157 the distribution of COVID-19 according to gender (15). Other studies have shown that SARS-
158 CoV and MERS-CoV also infect more men than women (16). The low vulnerability of women
159 to viral infections is thought to be caused by the protective effect of the X chromosome (17)
160 and the effects of sex hormones such as estrogen and progesterone, which play an important
161 role in the immune system (18).

162 COVID-19 comorbidities were found in several patients in this study, such as hypertension,
163 cardiovascular disease, and diabetes. This is consistent with a systematic review study and
164 meta-analysis that shows that the major comorbidities are hypertension and diabetes,
165 followed by cardiovascular disease. (19). This chronic disease is related to the pathogenesis
166 of COVID-19. Chronic disease has a standard picture similar to infectious diseases, especially
167 in the immune system (20). Metabolic disorders can reduce immune function by inhibiting
168 the work of macrophages and lymphocyte function, thus making a person more susceptible
169 to complications from a disease (21).

170 The main clinical symptoms of COVID-19 in this study were cough, sore throat, and fever. This
171 is consistent with a meta-analysis study showing that the main clinical symptoms of COVID-
172 19 patients are fever and cough (15). COVID-19 patients generally present with similar
173 symptoms, such as fever, cough, and sore throat. Most patients with SARS-CoV-2 infection
174 will appear with mild flu-like symptoms (22).

175 Several COVID-19 patients had anemia, which is a low level of hemoglobin and red blood cell
176 count. This can be caused by the initial condition of the patient at the hospital who already
177 has anemia. Iron deficiency is a form of anemia that is common in patients admitted to
178 hospitals in Indonesia (23). A study found that iron deficiency anemia can affect the immune
179 response and cytokine activity in the body (24). This can increase the vulnerability to be
180 infected with COVID-19.

181 Another abnormal laboratory finding in COVID-19 patients here is an increase in AST and ALT
182 levels which are parameters of liver function. This is similar to other studies that the
183 laboratory examination results of COVID-19 patients showed that 76.3% had impaired liver
184 function (25). Impaired liver function related to COVID-19 can be caused directly by a viral
185 infection or other conditions such as the use of drugs that are hepatotoxic or due to systemic
186 inflammatory responses, hypoxic conditions due to respiratory distress, and multiorgan

187 dysfunction (26). If impaired liver function occurs, hepatoprotective drugs are recommended
188 to be given to these patients (27).

189 Abnormal chest x-ray images of pneumonia were only found in 6 patients in this study. This
190 is similar to other studies that found that consolidation and ground-glass opacity are chest x-
191 ray findings in patients with positive confirmation of COVID-19 (28). The description of
192 bilateral pneumonia with ground-glass opacity appearance in this study is consistent with the
193 results of a systematic review and meta-analysis of COVID-19 (29).

194 All patients are in mild condition and none of the patients admitted to intensive care. This is
195 consistent with studies that estimate the number of asymptomatic patients for COVID-19
196 around less than half (30). As of May 24, 2020, only 3 fatal cases of laboratory-confirmed
197 COVID-19 were reported in East Kalimantan (13). Most of the COVID-19 patients admitted to
198 hospitals in East Kalimantan are in mild condition.

199 The average length of time a patient starts in the hospital until the laboratory positive COVID-
200 19 is confirmed is more than 10 days. This is due to the nasopharyngeal swab sample from
201 Abdul Wahab Sjahranie Hospital being sent to the Center for Health Laboratory of the
202 Ministry of Health in Surabaya, Indonesia. This laboratory serves the examination of reference
203 specimens from the provinces of East, Central, South, and North Kalimantan (12). As of May
204 24, 2020, there were 276 positive cases in East Kalimantan, 308 in Central Kalimantan, 599 in
205 South Kalimantan, and 164 North Kalimantan (31). The large number of samples that must be
206 examined up to 4 provinces makes the slow progress of laboratory examination. Patients
207 must wait a long time for laboratory confirmation results of COVID-19.

208 The average length of hospital admission patients to discharge is more than 30 days. This is
209 because COVID-19 patients with clinical improvement can only be discharged from the
210 hospital if the results of RT-PCR examination two days in a row show negative results (32).
211 Based on the explanation above, the large number of samples that had to be examined from
212 4 provinces in Kalimantan by the Center for Health Laboratory of the Ministry of Health made
213 patients wait longer for negative COVID-19 confirmation results.

214 Our study has several limitations. First, with a limited number of cases, this is a series of small
215 patient cases. Data collection for larger studies will help to better determine the clinical
216 picture and risk factors for this disease. Second, there is a potential exposure bias and no
217 children were reported as patients in this study. More efforts must be made to answer these
218 questions in further research.

219

220 **Conclusion**

221 All COVID-19 patients in this study were in mild condition with symptoms of fever, cough, and
222 sore throat. Most patients were male and had comorbidities which can increase the risk of
223 COVID-19. Anemic conditions and increased AST/ALT levels in some patients need attention
224 during patient care in the hospital. Although all patients are in mild condition, the inability of
225 a local laboratory in East Kalimantan to check for positive confirmation of COVID-19 extended
226 the admission period of the patient in the hospital unnecessarily. Therefore, the availability
227 of RT-PCR tests at Abdul Wahab Sjahranie Hospital Samarinda will greatly assist the further
228 management of COVID-19 patients.

229

230 **REFERENCES**

- 231 1. Richman D, Whitley R, Hayden F. *Clinical Virology*. 4th ed. Washington: ASM Press;
232 2016.
- 233 2. Drosten C, Günther S, Preiser W, Van Der Werf S, Brodt HR, Becker S, et al.
234 Identification of a novel coronavirus in patients with severe acute respiratory
235 syndrome. *N Engl J Med*. 2003;348(20):1967–76.
- 236 3. Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a
237 novel coronavirus from a man with pneumonia in Saudi Arabia. *N Engl J Med*.
238 2012;367(19):1814–20.
- 239 4. WHO. Summary of probable SARS cases with onset of illness from 1 November 2002
240 to 31 July 2003. World Health Organization. 2003.
- 241 5. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). World Health
242 Organization. 2019.
- 243 6. WHO. Novel Coronavirus – China. World Health Organization. 2020.
- 244 7. Gorbalenya AE. Severe acute respiratory syndrome-related coronavirus–The species
245 and its viruses, a statement of the Coronavirus Study Group. *BioRxiv*. 2020;
- 246 8. Worldometer. COVID-19 Coronavirus Pandemic. Worldometer. 2020.
- 247 9. Gorbiano MI. BREAKING: Jokowi announces Indonesia’s first two confirmed COVID-19
248 cases. *The Jakarta Post*. 2020 Mar 2;
- 249 10. Kumparan. Kasus Positif Corona Pertama di Kaltim, Pasien Pernah Ikut Seminar di
250 Bogor. *Kumparan*. 2020 Mar 18;

- 251 11. Maulia E. Jokowi announces Indonesia's new capital in East Kalimantan. *Nikkei Asian*
252 *Review*. 2019 Aug 26;
- 253 12. Ministry of Health Republic of Indonesia. COVID-19. *Infeksi Emerging*. 2020.
- 254 13. Dinas Kesehatan Provinsi Kalimantan Timur. Dinas Kesehatan Provinsi Kalimantan
255 Timur [Internet]. COVID-19. 2020 [cited 2020 May 24]. Available from:
256 <https://covid19.kaltimprov.go.id>
- 257 14. Kementerian Kesehatan RI. Situasi Terkini Perkembangan Coronavirus Disease
258 (COVID-19). Kementerian Kesehatan RI. 2020.
- 259 15. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. COVID-19 patients'
260 clinical characteristics, discharge rate, and fatality rate of meta-analysis. *J Med Virol*.
261 2020;92(6):577–83.
- 262 16. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory
263 syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. *Int J*
264 *Infect Dis*. 2016;49:129–33.
- 265 17. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-based
266 differences in susceptibility to severe acute respiratory syndrome coronavirus
267 infection. *J Immunol*. 2017;198(10):4046–53.
- 268 18. Jaillon S, Berthenet K, Garlanda C. Sexual dimorphism in innate immunity. *Clin Rev*
269 *Allergy Immunol*. 2017;1–14.
- 270 19. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the
271 novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-
272 analysis. *Int J Infect Dis*. 2020;
- 273 20. Odegaard JI, Chawla A. Connecting type 1 and type 2 diabetes through innate
274 immunity. *Cold Spring Harb Perspect Med*. 2012;2(3):p.a007724.
- 275 21. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two
276 epidemics. *Lancet Infect Dis*. 2009;9(12):737–46.
- 277 22. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected
278 with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497–506.
- 279 23. Syam AF, Sobur CS, Abdullah M, Makmun D. Nutritional Status of Hospitalized
280 Nonsurgery Patients at A Nationwide Referral Hospital in Indonesia. *J Int Dent Med*
281 *Res*. 2018;11(2):732–9.
- 282 24. Ekiz C, Agaoglu L, Karakas Z, Gurel N, Yalcin I. The effect of iron deficiency anemia on

- 283 the function of the immune system. *Hematol J*. 2005;5(7):579.
- 284 25. Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. Characteristics of liver tests in COVID-19
285 patients. *J Hepatol*. 2020;
- 286 26. Feng G, Zheng KI, Yan QQ, Rios RS, Targher G, Byrne CD, et al. COVID-19 and liver
287 dysfunction: current insights and emergent therapeutic strategies. *J Clin Transl*
288 *Hepatol*. 2020;8(1):18.
- 289 27. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges.
290 *Lancet Gastroenterol Hepatol*. 2020;5(5):428–30.
- 291 28. Wong HYF, Lam HYS, Fong AHT, Leung ST, Chin TWY, Lo CSY, et al. Frequency and
292 distribution of chest radiographic findings in COVID-19 positive patients. *Radiology*.
293 2020;p.201160.
- 294 29. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R,
295 Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features
296 of COVID-19: A systematic review and meta-analysis. *Travel Med Infect Dis*.
297 2020;p.101623.
- 298 30. Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung S, Hayashi K, et al. Estimation of
299 the asymptomatic ratio of novel coronavirus infections (COVID-19). *medRxiv*. 2020;
- 300 31. Gugus Tugas Percepatan Penanganan COVID-19. Situasi virus COVID-19 di Indonesia.
301 Gugus Tugas Percepatan Penanganan COVID-19. 2020.
- 302 32. Direktorat Jenderal Pencegahan dan Pengendalian Penyakit. Pedoman Pencegahan
303 dan Pengendalian Coronavirus Disease (COVID-19). Jakarta, Indonesia: Kementerian
304 Kesehatan RI; 2020.
- 305